, Tracking Stock Market Picks
Enter Symbol:
Cephalon, Inc. (CEPH) [hlAlert]

up 22.61 %

Cephalon, Inc. (CEPH) rated Outperform with price target $68 by Oppenheimer

Posted on: Friday,  Feb 11, 2011  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Cephalon, Inc. (NASDAQ: CEPH) on 02/11/2011. Previously Oppenheimer rated Outperform Cephalon, Inc. (NASDAQ: CEPH) on 10/29/2010., when
the stock price was $66.46. Since then, Cephalon, Inc. has gained 22.62% as of 10/13/2011's recent price of $81.49.
If you would have followed the previous Oppenheimer's recommendation on CEPH, you would have gained 22.61% of your investment in 349 days.

Cephalon is an international biopharmaceutical company focused on thediscovery, development and marketing of products to treat sleep disorders,neurological disorders, cancer and pain. In addition to an active research and development program, they market products in the United States and various countries in Europe.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/11/2011 8:25 AM Buy
58.56 68.00
as of 12/30/2011
1 Week   
1 Month   
3 Months up  0.97 %
1 YTD up  32.03 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/29/2010 8:25 AM Buy
66.46 75.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy